Kintara Therapeutics Inc announces first international site activation in its Phase 2/3 clinical trial for glioblastoma multiforme (GBM)
The treatment arm was activated in Canada at Toronto’s Sunnybrook Health Sciences Centre, bringing the current total to 31 locations
Source: proactiveinvestors.com